<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02529878</url>
  </required_header>
  <id_info>
    <org_study_id>ECGC-0001</org_study_id>
    <nct_id>NCT02529878</nct_id>
  </id_info>
  <brief_title>Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer</brief_title>
  <official_title>A Prospective Feasibility Study for Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Zhejiang Chinese Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Zhejiang Chinese Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prognosis of metastatic gastric cancer is poor. Chemotherapy occasionally converts an&#xD;
      initially unresectable gastric cancer to a resectable cancer. Previous studies showed&#xD;
      patients with unresectable gastric cancer may obtain a survival benefit from chemotherapy and&#xD;
      subsequent curative surgery. The key of conversion therapy of initially unresectable&#xD;
      metastatic GC is the high response rate. Apatinib, a novel targeted inhibitor of VEGF&#xD;
      receptor 2 (VEGFR2), shows significant antitumor activity in the patients with GC. The&#xD;
      purpose of this study is to investigate the efficacy and safety of S1/Paclitaxel chemotherapy&#xD;
      plus Apatinib in the conversion therapys of metastatic gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will apply SPA regimen for coversional therapy to abtain high response&#xD;
      rate.&#xD;
&#xD;
      Paclitaxelï¼š150 mg/m2 i.v.3h , given on the first day. Apatinib, oral ,initial dose :500mg,&#xD;
      QD, after meal ( try to take the medicine at the same time of the day ).&#xD;
&#xD;
      Dose adjustment: Down-regulate the dosage to 250 mg per day at the first time. If the patient&#xD;
      totally recovers from the toxic reaction after the regulation, we could up-regulate the&#xD;
      dosage back to the former level. If the down-regulation occurs again according to the&#xD;
      protocol , then the up-regulation will be forbidden.&#xD;
&#xD;
      S-1 dosage: According to the body surface area, the initial dosage of S-1 is decided by the&#xD;
      following criteria. Take the medicine twice daily (after breakfast and supper) for 2 weeks,&#xD;
      then suspend for 1 week.&#xD;
&#xD;
      Preventive medication: To prevent serious allergic reaction of Paclitaxel, preventive&#xD;
      medication should be given in advance. We usually give dexamethasone 20mg orally 12 and 6&#xD;
      hours before the Paclitaxel, and diphenhydramine (or something analogous) 50 mg, cimetidine&#xD;
      300mg (or ranitidine 50mg) I.V. 30-60 minutes before the Paclitaxel.&#xD;
&#xD;
      Repeat the therapeutic schedule every 3 weeks. 3 cycles of neoadjuvant chemotherapy before&#xD;
      surgery, stop Apatinib in the last cycle.&#xD;
&#xD;
      3 cycles of adjuvant chemotherapy including S-1 and Apatinib 4 to 6 weeks after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>radical resection rate</measure>
    <time_frame>4 months</time_frame>
    <description>the radical resection rates</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>the overall survival time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>number and degree of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reaction rate</measure>
    <time_frame>4 months</time_frame>
    <description>the reaction rate of chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>conversion treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>after 3 cycles S1/Paclitaxel chemotherapy plus Apatinib,subsequent surgery will be conducted with curative intent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S1/Paclitaxel chemotherapy plus Apatinib</intervention_name>
    <description>S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:500mg once daily</description>
    <arm_group_label>conversion treatment</arm_group_label>
    <other_name>SPA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  unresectable gastric cancer as proven histologically(AJCC, version 7) under any&#xD;
             following condition: unable radical excision due to the local metastasis of invasion&#xD;
             metastasis to the lymph node beside the abdominal aorta, non-extensive metastasis to&#xD;
             liver( not more than three metastatic foci of radical excision), Peritoneal&#xD;
             metastasis(CY1,P1,P2), kukerburg tumor&#xD;
&#xD;
          -  Definitely diagnosed as above stage of gastric cancer before operation via CT of MRI,&#xD;
             ultrasonic endoscopy, PET-CT, or through the laparoscopic exploration if necessary&#xD;
&#xD;
          -  Untreated(e.g. radiotherapy, chemotherapy, target therapy and immunotherapy)&#xD;
&#xD;
          -  Negative HER-2 state&#xD;
&#xD;
          -  ECOG(Eastern Cooperative Oncology Group) :0~2&#xD;
&#xD;
          -  Age: 18~75 years old&#xD;
&#xD;
          -  Normal hemodynamic indices before the recruitment(including blood cell count and&#xD;
             liver/kidney function ). For example: WBC&gt;4.0*109/L, NE&gt;1.5*109/L, PLT&gt;100*109/L,&#xD;
             BIL&lt;1.5 times of upper limit of normal reference value, ALT and AST&lt;2.5 times of upper&#xD;
             limit of normal reference value, and CRE&lt;1.2mg/dl&#xD;
&#xD;
          -  Good cardiac function before the recruitment, no seizure of myocardial infarction in&#xD;
             past half years, and controllable hypertension and other coronary heart disease&#xD;
&#xD;
          -  Not concomitant with other uncontrollable benign disease before the recruitment(e.g.&#xD;
             the infection in the kidney, lung and liver)&#xD;
&#xD;
          -  Not participating in other clinical trials before and during the treatment&#xD;
&#xD;
          -  Signed the Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  not conforming above inclusion conditions&#xD;
&#xD;
          -  Distal metastasis to lung, brain, and bone&#xD;
&#xD;
          -  Ever operation on the stomach&#xD;
&#xD;
          -  Operation intolerance due to other systemic basic disease&#xD;
&#xD;
          -  Ever administrated with other drugs(including TCM drugs) before the recruitment, or no&#xD;
             guarantee of progress according to the study requirement after recruitment&#xD;
&#xD;
          -  Allergy to the drugs in this protocol&#xD;
&#xD;
          -  Pregnant and lactating women&#xD;
&#xD;
          -  Women at childbearing age and of pregnancy desire during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiangdong Cheng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Zhejiang Chinese Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiangdong Cheng, MD</last_name>
    <phone>+86-057187070965</phone>
    <email>getfar@foxmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Zhejiang Chinese Medical University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiangdong Cheng, MD</last_name>
      <phone>+86-057187970965</phone>
      <email>getfar@foxmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>August 19, 2015</study_first_submitted>
  <study_first_submitted_qc>August 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2015</study_first_posted>
  <last_update_submitted>July 23, 2016</last_update_submitted>
  <last_update_submitted_qc>July 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastric caner</keyword>
  <keyword>Apatinib</keyword>
  <keyword>S1</keyword>
  <keyword>conversion therapy</keyword>
  <keyword>metastatic gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

